Biocon announces pivotal clinical data for Yesafili biosimilar

Biocon announces pivotal clinical data for Yesafili biosimilar. Biocon has announced the publication of pivotal clinical data supporting the effectiveness of Yesafili, its biosimilar to Eylea® (Aflibercept), in a press release dated July 09, 2026. The data reinforces the drug’s potential in ophthalmic indications and could support future regulatory approvals and market expansion. Positive clinical outcomes may enhance commercial prospects in the growing biosimilars market.

📊 STOCKS: BIOCON | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma